Healthcare providers often recommend continuing the program until clients achieve their target weight and establish healthier eating and activity patterns
A phase 3 clinical study with a higher dosage of daily 25 and 50 mg of oral semaglutide is about to be initiated, in the hope of obtaining promising data for both body weight reduction and cardiovascular benefits [34,37]
Importantly, highlighting the increasing popularity of the drugs, 19.5% of participants indicated that while they have not yet used a GLP-1 medication, they are considering using one in the next year
Supplement Facts: GLP-1 Support Blend 650 mg
Peptide potency depends on proper storage and handling
Some patients experience mild nausea, bloating, or digestive discomfort during the first few weeks as the body adjusts